Gooding is one of the world's most-cited biosensor scientists (inaugural editor-in-chief of ACS Sensors) and runs a group of over thirty researchers spanning surface chemistry, electrochemistry and nanomedicine. The sensing programme that matters here is the move from ensemble to digital, single-molecule-resolved detection: nanoparticle-tethered electrochemical sensors in which single binding events are counted rather than averaged, nanopore blockade sensors for protein biomarkers such as PSA, amplification-free nucleic-acid detection, and antifouling surface chemistries that make any of this work in real biological fluid. He has a strong commercialisation record (AgaMatrix glucose sensors). Positioned against the established body of NV-ensemble quantum sensing work — DEER, nanoscale NMR and T1 relaxometry protocols operating at pT/sqrt(Hz) field sensitivity — his single-molecule-counting philosophy is the biosensing analogue of moving from a pT/sqrt(Hz) NV ensemble to single-spin detection: in both cases the sensitivity gain comes from resolving individual events rather than improving an averaged signal. He is also the obvious collaborator for anyone trying to functionalise a diamond or nanoparticle quantum sensor for a real analyte.